Tekla Life Sciences Investors (HQL) 18.59 $HQL
Post# of 273249
Tekla Healthcare Opportunities Fund Paid Distribution
BusinessWire - Wed Aug 31, 10:09AM CDT
On August 31, 2016, Tekla Healthcare Opportunities Fund paid a monthly stock distribution of $0.1125 per share. It is currently estimated that this distribution is derived from net investment income and long-term capital gains. The composition of this and subsequent distributions may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $35,797,669, of which $16,088,629 represents net unrealized appreciation of portfolio securities.
HQL: 18.59 (+0.15), THQ: 17.42 (+0.20), THW: 15.14 (+0.10), HQH: 24.36 (+0.23)
Tekla World Healthcare Fund Paid Distribution
BusinessWire - Wed Aug 31, 10:09AM CDT
Tekla World Healthcare Fund paid a monthly stock distribution of $0.1167 per share. It is currently estimated that this distribution is derived from short-term capital gains. The composition of this and subsequent distributions may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized depreciation of portfolio securities and net realized gains on sale of securities is -$36,247,142, of which $72,659,248 represents net unrealized depreciation of portfolio securities.
THQ: 17.42 (+0.20), HQL: 18.59 (+0.15), THW: 15.14 (+0.10), HQH: 24.36 (+0.23)
Tekla Life Sciences Investors Paid Distribution
BusinessWire - Fri Aug 12, 9:27AM CDT
On August 12, 2016, Tekla Life Sciences Investors paid a distribution of $0.82 per share. It is currently estimated that $0.8089 of this distribution is derived from long-term capital gains and $0.0111 is derived from return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized losses on sale of securities is $105,297,567, of which $107,196,306 represents net unrealized appreciation of portfolio securities.
THQ: 17.42 (+0.20), HQL: 18.59 (+0.15), THW: 15.14 (+0.10), HQH: 24.36 (+0.23)
Tekla Funds Announce Results of Joint Annual Shareholders Meeting
BusinessWire - Tue Jun 14, 1:02PM CDT
The Boards of Trustees of Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW) are pleased to announce the results from the Funds' annual shareholder meeting held today.
THQ: 17.42 (+0.20), HQL: 18.59 (+0.15), THW: 15.14 (+0.10), HQH: 24.36 (+0.23)
Tekla Healthcare Investors Paid Distribution
BusinessWire - Thu Mar 31, 11:59AM CDT
On March 31, 2016, Tekla Healthcare Investors paid a distribution of $0.61 per share. It is currently estimated that this distribution is derived from long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $209,865,139, of which $197,524,925 represents net unrealized appreciation of portfolio securities.
THQ: 17.42 (+0.20), HQL: 18.59 (+0.15), THW: 15.14 (+0.10), HQH: 24.36 (+0.23)
H&Q Life Sciences Investors Has Returned 26.5% Since SmarTrend Recommendation (HQL)
Comtex SmarTrend(R) - Wed Feb 03, 6:25PM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 2 months, H&Q Life Sciences Investors has returned 26.52% as of today's recent price of $17.64.
HQL: 18.59 (+0.15)
22.1% Return Seen to Date on SmarTrend H&Q Life Sciences Investors Call (HQL)
Comtex SmarTrend(R) - Wed Jan 27, 5:16PM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 2 months, H&Q Life Sciences Investors has returned 22.14% as of today's recent price of $18.69.
HQL: 18.59 (+0.15)
H&Q Life Sciences Investors Down 25.6% Since SmarTrend Downtrend Call (HQL)
Comtex SmarTrend(R) - Wed Jan 20, 11:13AM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 1 month, H&Q Life Sciences Investors has returned 25.56% as of today's recent price of $17.87.
HQL: 18.59 (+0.15)
H&Q Life Sciences Investors Shares Down 15.4% Since SmarTrend's Sell Call (HQL)
Comtex SmarTrend(R) - Tue Jan 12, 5:08PM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 1 month, H&Q Life Sciences Investors has returned 15.35% as of today's recent price of $20.32.
HQL: 18.59 (+0.15)